EU drug approval should include price evaluation, says expert panelBMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l6591 (Published 19 November 2019) Cite this as: BMJ 2019;367:l6591
- Elisabeth Mahase
- The BMJ
New drugs should not be approved for sale in the European Union (EU) unless pharmaceutical companies agree to a fair price, an expert panel has urged.
Speaking at the European Public Health Alliance’s Universal Access and Affordable Medicines forum in Brussels on 14 November, experts from across the EU spoke about the need for greater transparency from the pharmaceutical industry to make drug pricing fairer.
Carin Uyl-de Groot, director of the Institute for Medical Technology Assessment at Erasmus University, Rotterdam, said, “We need a change in law. After European Medicines Agency (EMA) registration, we need to identify …